A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer

Trial Profile

A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms tnAcity
  • Sponsors Abraxis BioScience; Celgene Corporation
  • Most Recent Events

    • 30 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 15 Mar 2017 This trial has been completed in UK according to European Clinical Trials Database.
    • 14 Mar 2017 This trial has been discontinued in United Kingdom (end date: 28 Oct 2016), according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top